Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of IC51 (Ixiaro) in Pediatric Travelers
NCT01047839Phase 3Completed
- Sponsor
- Valneva
- Start
- Jan 2010
- Primary completion
- Aug 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 3, open-label trial of Japanese encephalitis inactivated vaccine in Japanese encephalitis (JE) (3 arms), sponsored by Valneva. Primary endpoint: Rate of Subjects With Serious Adverse Events (SAEs) and Medically Attended AEs at Day 56. Started Jan 2010; status: completed.
02
Drugs
Japanese encephalitis inactivated vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on NCT01047839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01047839.